ArticleJournal of clinical oncology : official journal of the American Society of Clinical Oncology2025

Phase I Dose-Escalation Results for the Delta-Like Ligand 3/CD3 IgG-Like T-Cell Engager Obrixtamig (BI 764532) in Patients With Delta-Like Ligand 3+ Small Cell Lung Cancer or Neuroendocrine Carcinomas.

Martin Wermke et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.